The effects of dexmedetomidine combined butorphanol tartrate on inflammation, oxidative stress response and neuronal function in patients with intracranial hematoma scavenging

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900025962

Enrollment

Unknown

Registered

2019-09-15

Start date

2019-09-22

Completion date

Unknown

Last updated

2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral hemorrhage

Interventions

Dexmedetomidine group:Dexmedetomidine was injected intravenously at 0.6 ug/kg and then maintained at 0.4 ug/kg/h

Butorphanol tartrate group:Intravenous infusion of butorphanol tartrate 40 ug/kg

Dexmedetomidine + butorphanol tartrate group:Dexmedetomidine 0.6 ug/kg was injected intravenously, and then 0.4 ug/kg/h was maintained

butorphanol tartrate was also injected intravenously.

control group:nothing

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. According to CT/MRI, intracranial hemorrhage should be operated on: (1) hypertensive intracerebral hemorrhage: (1) lobar hemorrhage (> 30 mL); basal ganglia hemorrhage (> 30 mL); thalamic hemorrhage (> 10 mL); cerebellar hemorrhage (> 10 mL); intraventricular hemorrhage, causing obstructive hydrocephalus and casting ventricular hemorrhage; Although intracranial hemorrhage did not reach the surgical indications; (2) Traumatic intracranial hemorrhage: 1) acute epidural hematoma, subdural hematoma, supratentorial hematoma (> 30 mL), subtentorial hematoma (> 10 mL), stable condition, short-term not only in patients with cerebral hernia; 2) subacute and chronic subdural hematoma; 3) intracranial hematoma refers to hypertensive surgical indications; 4) craniocerebral injury; Traumatic patients with ventricular hemorrhage and obstructive hydrocephalus (Rao and Wang, 2014); 2. Removal of hematoma by craniotomy was performed; 3. Aged 18 to 70 years; 4. American Society of Anesthesiologists (Fitz-Henry, 2011) I-IV.

Exclusion criteria

Exclusion criteria: 1. Patients with abnormal coagulation function; 2. Haematoma caused by aneurysm or malformation was identified; 3. People with a history of drug allergy in the past; 4. Alcohol, opioid or tranquilizer addicts; 5. Patients with other serious diseases, such as severe hypertension and cardiovascular diseases, malignant tumors, autoimmune diseases, mental disorders and diabetes mellitus with poor blood sugar control; 6. Liver and kidney dysfunction; 7. Long-term history of opioid use; 8. Late stage of brain hernia or brain death; 9. Infected persons before injury; 10. Women in pregnancy.

Design outcomes

Primary

Measure	Time frame
Glasgow Coma Score;Inflammatory factors in plasma;Oxidative stress factors in plasma;physiological index;	—

Countries

China

Contacts

Public ContactZongze Zhang

Zhongnan Hospital of Wuhan University

478882560@qq.com+86 13517232805

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026